Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2002

View Archived Issues

Abbott presents new erythromycins with improved GI tolerability

New hydroxamic acids with MMP/TNF-alpha-inhibitory activity from Fujisawa

GSK presents novel inhibitors of IKK-beta

TNF-alpha production inhibitors in early development at Nikken Chemicals

Kissei claims SGLT2 inhibitors for use in diabetes and obesity

New alpha4 integrin-selective cell adhesion inhibitors identified at Japanese lab

Axokine enters study in obese patients with type 2 diabetes

Patient enrollment completed in two DAC:opioid phase II trials

New mechanisms of action reported for Esterom in primary and secondary hyperalgesia

Neurodex completes phase II/III trial in emotional lability

Hypoxic cell cytotoxin licensed to KuDOS

Azapinoindoles with high affinity for the 5-HT2C receptor subtype designed at Pharmacia

Potent analgesic agents emerge from a series of pyrrole alkylamide analogues

Strategies in the development of 5-HT2A-selective antagonists

Safety data for NBI-6024 in adolescent type 1 diabetics support further development

HIM2 examined for systemic pharmacokinetics in dogs, oral absorption in diabetic patients

ADA news: dual PPARalpha/gamma agonist has beneficial effects on glucose, lipids

BMS-298585 exerts both glucose- and lipid-lowering effects in animal models

Procyon updates development of key product candidates

Continued expression of anti-HIV-1 antisense RNA up to 24 months after HGTV-43 gene therapy

InNexus acquires SAT rights to 1F7

AEterna updates Neovastat progress

CpG-7909 enters phase I/II in malignant melanoma

FDA advisory committee sets date to review Vanlev

Novogen initiates second clinical trial of NV-07a

Oncolytics to acquire interest in Transition Therapeutics

Zyprexa approved in E.U. for manic episodes associated with bipolar disorder

Extina enters phase III for seborrheic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...